Download PDF
Horm Metab Res 1991; 23(3): 135-138
DOI: 10.1055/s-2007-1003633
Clinical

© Georg Thieme Verlag, Stuttgart · New York

Serum Bone Gla Protein (BGP) During Treatment of Hyperthyroidism and Hypothyroidism

A Longitudinal StudyJ. Faber, H. Perrild, J. S. Johansen
  • Department of Medicine E, Frederiksberg Hospital, Copenhagen
  • Department of Medicine C, Bispebjerg University Hospital, Copenhagen
  • Department of Clinical Chemistry, Glostrup University Hospital, Glostrup
  • Department of Medicine F, Herlev University Hospital, Herlev, Denmark
Further Information

Publication History

1989

1990

Publication Date:
14 March 2008 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Serum bone gamma-carboxyglutamic acid-containing (Gla) protein (BGP) was measured before and with initially 2 weeks, later 4-8 weeks intervals for 20-58 weeks during treatment of patients with hyperthyroidism (n = 10) and hypothyroidism (n = 4).

Biochemical euthyroidism was obtained in the hyperthyroid patients after a median of 3 weeks (range 1-8 weeks), and in the hypothyroid patients after a median of 17 weeks (range 10-27 weeks). Serum BGP levels closely followed the thyroid state, being high respectively low in the hyperthyroid and hypothyroid state and reaching a stable plateau just at the time biochemical euthyroidism was obtained.

These data suggest that osteoblastic activity is enhanced in hyperthyroidism and reduced in hypothyroidism, and that normalization occurs in close conjunction with the normalization of the thyroid state, without any delay, indicating a direct effect on the function of the excisting osteoblasts by the thyroid hormones.

Key words

Bone-Gla-Protein - Hyperthyroidism - Hypothyroidism

      >